ARKG - ETF AI Analysis
Top Page
ARK Genomic Revolution ETF (ARKG)
ARKG’s rating reflects a mix of promising growth stories and meaningful risks in the genomics space. Stronger holdings like CareDx, Natera, Eli Lilly, Illumina, and Guardant Health support the fund with solid financial performance, revenue growth, and positive technical trends, plus strategic moves such as acquisitions, partnerships, and product launches. However, weaker names like Twist Bioscience and Crispr Therapeutics, which face profitability, cash flow, and bearish technical challenges, along with the fund’s concentration in a single high-risk sector (genomics/biotech), hold back the overall rating and add volatility risk.
ARKG vs. SPDR S&P 500 ETF (SPY)
- AUM
- 2.09B
- Region
- Global
- Expense Ratio
- 0.75%
- Beta
- 1.61
- Issuer
- ARK
- Inception Date
- Oct 31, 2014
- Dividend Yield
- 0.77%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
ARKG Summary
ARK Genomic Revolution ETF (ARKG) is a fund focused on the theme of genomics and genetic innovation, mainly in the healthcare sector. It invests in companies working on DNA sequencing, gene editing, and advanced medical testing. Some well-known names in the fund include Eli Lilly and Illumina. Investors might consider ARKG if they want growth potential from cutting-edge medical and biotech breakthroughs and a way to spread their money across many genomics companies instead of picking just one stock. A key risk is that these biotech stocks can be very volatile, so the ETF’s price can rise and fall sharply with market and science news.
How much will it cost me?
This ETF has an expense ratio of 0.75%, which means you’ll pay about $7.50 per year for every $1,000 you invest. That’s higher than the average ETF because ARKG is actively managed, with a team picking specialized genomics stocks rather than just tracking a broad market index.
What would affect this ETF?
ARKG could benefit if breakthroughs in gene editing, diagnostics, and AI-driven healthcare gain wider adoption, and if global health spending and supportive regulations continue to favor innovative biotech companies like its top holdings. On the downside, higher interest rates, stricter drug and genetic testing rules, clinical trial setbacks, or a downturn in the healthcare and biotech sector globally could hurt the fund’s performance, especially given its heavy concentration in a small group of specialized companies.
ARKG Top 10 Holdings
ARKG is a pure play on cutting-edge genomics, with most of its firepower in U.S. health-care innovators. The fund leans heavily on high-beta names like 10x Genomics and Twist Bioscience, which have been rising over the past few months but recently lost some steam, adding volatility to returns. Tempus AI is another key driver with improving momentum but still mixed signals. On the brighter side, Illumina and Eli Lilly provide steadier support, helping offset the more erratic gene-editing and sequencing plays. Overall, it’s a concentrated bet on the genomic revolution, not a broad market safety net.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 TEM | Tempus AI, Inc. Class A | 9.51% | $204.22M | $14.30B | -12.30% | 52Neutral |
 TXG | 10x Genomics | 7.76% | $166.68M | $8.03B | 376.57% | 60Neutral |
 TWST | Twist Bioscience | 7.86% | $168.80M | $8.50B | 344.41% | 43Neutral |
 CRSP | Crispr Therapeutics AG | 5.34% | $114.71M | $4.83B | -19.33% | 40Underperform |
 GH | Guardant Health | 5.12% | $110.00M | $22.91B | 76.91% | 61Neutral |
 ABSI | AbSci | 5.10% | $109.57M | $1.66B | 143.31% | 49Neutral |
 NTRA | Natera | 4.66% | $100.14M | $54.62B | 96.05% | 73Outperform |
 LLY | Eli Lilly & Co | 4.47% | $95.98M | $1.33T | 57.20% | 72Outperform |
 CDNA | CareDx | 4.51% | $96.93M | $4.51B | 498.98% | 77Outperform |
 ILMN | Illumina | 4.36% | $93.68M | $34.26B | 98.52% | 71Outperform |
ARKG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ARKG, the sentiment is Neutral. The current price of 49.51 is below the 20-day moving average (MA) of 49.72, below the 50-day MA of 49.93, and above the 200-day MA of 37.52, indicating a neutral trend. The MACD of 0.24 indicates Negative momentum. The RSI at 48.42 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ARKG.
ARKG Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| ARKG | $49.51 | $49.00(-1.03% Downside) | $2.09B | 0.75% | 53Neutral |
 FWD | $118.08 | $156.37(32.43% Upside) | $3.08B | 0.65% | 64Neutral |
 ALAI | $41.13 | $58.92(43.25% Upside) | $2.42B | 0.58% | 67Neutral |
 BKGI | $42.62 | $47.97(12.55% Upside) | $1.94B | 0.55% | 68Neutral |
 ARKQ | $110.95 | $178.37(60.77% Upside) | $1.72B | 0.75% | 62Neutral |
 CHAT | $74.14 | $113.35(52.88% Upside) | $1.54B | 0.75% | 61Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ARKG | ARK Genomic Revolution ETF | 49.51 | 19.77 | 66.48% | |
| FWD | AB Disruptors ETF | 118.08 | 10.64 | 9.90% | |
| ALAI | Alger AI Enablers & Adopters ETF | 41.13 | 3.83 | 10.27% | |
| BKGI | BNY Mellon Global Infrastructure Income ETF | 42.62 | 3.93 | 10.15% | |
| ARKQ | ARK Autonomous Technology & Robotics ETF | 110.95 | -7.45 | -6.29% | |
| CHAT | Roundhill Generative AI & Technology ETF | 74.14 | 11.23 | 17.86% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.